<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00629317</url>
  </required_header>
  <id_info>
    <org_study_id>PISUI 2007-031</org_study_id>
    <nct_id>NCT00629317</nct_id>
  </id_info>
  <brief_title>Trial of Methyl Aminolevulinate Plus Aktilite in Facial Photodamage</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial of Methyl Aminolevulinate + Aktilite in Patients With Facial Photodamage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Antioquia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad de Antioquia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the efficacy of MAL + Aktilite versus placebo + Aktilite
      in facial photodamage in a randomized double blind trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been demonstrated that photodamage leads to wrinkles, mottled pigmentation,
      lentigines, telangiectasias, and textural changes, but more importantly, it can also lead to
      pre-cancerous conditions with the development of actinic keratosis (AK). The majority of
      photorejuvenation or photodamaged published studies have used 5-Amino-Levulinic acid (5-ALA)
      as a photosensitizer, and either a blue light or an Intense Pulsed Light source with a
      70%-95% global facial skin improvement. The molecular mechanism of such improvement is
      unknown, but activation of a non-specific immune response in addition to increased fibrosis
      and new collagen formation, have both been suggested.

      Methyl Aminolevulinate ( MAL) is another marketed photosensitizer mainly utilized in Europe.
      Lipophilicity, higher penetration depth and tumor selectivity has been advocated for MAL
      compared to 5-ALA. However, its effect in photodamaged skin has not been well documented.

      The aim of the study is to determine the efficacy of MAL + Aktilite (PDT) in facial
      photodamage.

      Study Type: Interventional

      Study Design: Randomized, double-Blind, placebo-controlled trial. Official Title: A
      randomized, double-Blind, placebo-controlled trial of Methyl Aminolevulinate + Aktilite in
      patients with facial photodamage.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy in facial global photodamage</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Facial fine lines, mottled pigmentation, tactile roughness, sallowness, erythema, telangiectasia</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological effect of MAL+PDT in fibrosis and new collagen formation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerance</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Skin Aging</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Moisturizer</intervention_name>
    <description>Cetaphil cream(For 3 hours) + Aktilite ( Photodynamic Therapy for 8 minutes)</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Cetaphil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methyl Aminolevulinate</intervention_name>
    <description>Methyl Aminolevulinate cream for 3 hours before Photodynamic therapy ( Aktilite)</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Metvix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects older than 35 years of age and less than 75 years of age

          -  Subjects with a photodamage grade of 2 or 3 according to a modified DoverÂ´s Global
             photodamage scale

          -  Subjects willing to participate according to protocol requirements.

          -  Patients with signed Informed Consent

          -  Patients with no exclusion criteria

        Exclusion Criteria:

          -  Pregnant or nursing females.

          -  Subjects with suspected porphyria, Systemic or cutaneous erythematosus lupus, or any
             other photosensitizing disorder or drug induced photosensitization.

          -  Any active infectious skin disorder ( Herpes simplex, molluscum contagiosum, facial
             warts )

          -  Subjects with less than 6 months of previous rejuvenation interfering treatments

          -  Subjects requiring concurrent treatment that would interfere with study objectives
             and/or assessments.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gloria Sanclemente, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coordinator Group of Investigative Dermatology-GRID</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hector I Garcia, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Coordinator GRAEPIC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IPS Universitaria - Universidad de Antioquia</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>01</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2008</study_first_submitted>
  <study_first_submitted_qc>March 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2008</study_first_posted>
  <last_update_submitted>March 13, 2009</last_update_submitted>
  <last_update_submitted_qc>March 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Gloria Sanclemente, MD, MSc.</name_title>
    <organization>Universidad de Antioquia</organization>
  </responsible_party>
  <keyword>Skin Aging</keyword>
  <keyword>Rejuvenation</keyword>
  <keyword>Photodynamic Therapy</keyword>
  <keyword>Methyl Aminolevulinate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
    <mesh_term>Methyl 5-aminolevulinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

